Connect
MJA
MJA

The Heart Protection Study: implications for clinical practice

Ian Hamilton-Craig
Med J Aust 2002; 177 (8): 407-408.
Published online: 21 October 2002

The benefits of statin therapy do not come without financial cost

The aim of the recently reported Heart Protection Study1 in the United Kingdom, with over 20 000 participants aged 40–80 years, was to establish whether statin therapy is of benefit to people who are at high risk of cardiovascular disease (CVD) but have average-to-low levels of total cholesterol and LDL-cholesterol. High-risk patients (defined as those having previous coronary heart disease, diabetes, stroke, or peripheral vascular disease) were treated with simvastatin (40 mg daily), antioxidant vitamins (20 mg beta-carotene, 250 mg vitamin C and 600 mg vitamin E daily) or placebo in a 2 × 2 factorial design.

  • Ian Hamilton-Craig

  • North Adelaide Cardiac Clinic, North Adelaide, SA.

Correspondence: ihc@medped-aust.com

Competing interests:

The author has served in an advisory capacity to government and non-government bodies, including pharmaceutical companies, and has received support for clinical research, presentations and attendance at scientific meetings from these bodies.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.